Baidu
map

Stroke:抗血小板治疗与颅内出血 !

2018-05-24 xing.T MedSci原创

由此可见,接受抗血小板药物治疗与局部脑叶MBs风险增加和CMBs患者脑出血发病率有关。

抗血小板治疗与脑微出血(CMBS)之间相关性的研究有限。近日,卒中领域权威杂志Stroke上发表了一篇研究文章,研究人员进一步研究了不同抗血小板治疗对局部脑叶和深部/幕下MBS的影响。

研究人员检索了PubMed和EMPASE等数据库中的相关研究,检索时间从1997年1月1日至2017年12月1日。研究人员计算了抗血小板治疗患者与未接受抗血小板治疗患者CMB发病率和分布(局部脑叶、深部/幕下)的合并比值比(OR),并计算了接受抗血小板治疗的CMBs患者与未接受抗血小板治疗的CMBs患者颅内出血发生率的OR值。

该分析共纳入了37项研究,20988名受试者。与未接受抗血小板治疗患者相比,接受抗血小板的患者发生CMBs更常见(合并的比值比为1.21;95%可信区间为1.07-1.36;P=0.002)。抗血小板治疗与局部脑叶MBs(OR为1.45,95%可信区间为1.15-1.84;P=0.002)显著相关,而与深部/幕下MBs(OR为1.37,95%可信区间为0.98-1.90;P=0.062)无关。与未接受抗血小板治疗患者相比,接受抗血小板的患者脑出血的发生率更高(OR为3.40,95%可信区间为2-5.78,P=0)。

由此可见,接受抗血小板药物治疗与局部脑叶MBs风险增加和CMBs患者脑出血发病率有关。

原始出处:


Jianting Qiu, et al. Antiplatelet Therapy, Cerebral Microbleeds, and Intracerebral Hemorrhage A Meta-Analysis.Stroke. 2018.https://doi.org/10.1161/STROKEAHA.118.021789

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=319202, encodeId=0c8b31920274, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 28 05:44:44 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318442, encodeId=a64531844206, content=这当中混杂因素多太太了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Fri May 25 12:01:09 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318350, encodeId=b1e0318350b2, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri May 25 07:22:14 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318288, encodeId=191e31828839, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri May 25 05:57:59 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318262, encodeId=4c35318262f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 24 23:12:29 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-28 大爰

    学习了谢谢分享!!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=319202, encodeId=0c8b31920274, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 28 05:44:44 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318442, encodeId=a64531844206, content=这当中混杂因素多太太了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Fri May 25 12:01:09 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318350, encodeId=b1e0318350b2, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri May 25 07:22:14 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318288, encodeId=191e31828839, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri May 25 05:57:59 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318262, encodeId=4c35318262f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 24 23:12:29 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-25 baihao215

    这当中混杂因素多太太了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=319202, encodeId=0c8b31920274, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 28 05:44:44 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318442, encodeId=a64531844206, content=这当中混杂因素多太太了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Fri May 25 12:01:09 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318350, encodeId=b1e0318350b2, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri May 25 07:22:14 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318288, encodeId=191e31828839, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri May 25 05:57:59 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318262, encodeId=4c35318262f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 24 23:12:29 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-25 张新亮1853311252142e2fm

    好文献学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=319202, encodeId=0c8b31920274, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 28 05:44:44 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318442, encodeId=a64531844206, content=这当中混杂因素多太太了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Fri May 25 12:01:09 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318350, encodeId=b1e0318350b2, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri May 25 07:22:14 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318288, encodeId=191e31828839, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri May 25 05:57:59 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318262, encodeId=4c35318262f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 24 23:12:29 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-25 1dd8c52fm63(暂无匿称)

    了解了解.继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=319202, encodeId=0c8b31920274, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon May 28 05:44:44 CST 2018, time=2018-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318442, encodeId=a64531844206, content=这当中混杂因素多太太了, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Fri May 25 12:01:09 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318350, encodeId=b1e0318350b2, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri May 25 07:22:14 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318288, encodeId=191e31828839, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri May 25 05:57:59 CST 2018, time=2018-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=318262, encodeId=4c35318262f5, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 24 23:12:29 CST 2018, time=2018-05-24, status=1, ipAttribution=)]
    2018-05-24 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

Lancet:三联抗血小板治疗的探索

TIA和缺血性卒中症状发作后早期复发风险最高,随后逐渐下降,一直持续几周。尽管阿司匹林能够降低早期复发风险,双联抗血小板治疗更加有效。无论选择何种抗血小板药物,两种药物总比单一药物有效。Chance研究发现对于中国小卒中或TIA患者,24h内使用阿司匹林联合氯吡格雷优于单独阿司匹林,能够降低90天复发。

CIT 2018:FDA新药审批顾问:抗血小板治疗的传说与现实

2018年3月22~25日,在第十六届中国介入心脏病学大会(CIT 2018)的药物学研讨会专场,与会专家聚焦临床研究热点,就ST段抬高型心肌梗死(STEMI)溶栓患者的优化抗栓策略、急性冠状动脉综合征(ACS)患者心肌梗死后的长期抗栓选择等进行了激烈的讨论交流。

Crit Care:荟萃分析:抗血小板治疗在急性呼吸窘迫综合征中的预防作用

抗血小板治疗并没有显著降低高危患者的医院死亡率。然而,抗血小板治疗是否与降低患者的ARDS发生率有关,但仍不清楚这种情况。

Circulation:添加西洛他唑强化抗血小板治疗可显著改善对氯吡格雷不敏感的患者预后

经皮冠状动脉介入治疗的患者对抗血小板药物的反应不同。对氯吡格雷反应不敏感的患者心脏缺陷事件风险高。Yi-Da Tang等人在单中心进行随机化的对照试验,对比强化的抗血小板疗法(两倍剂量的氯吡格雷[DOUBLE]或添加西洛他唑[TRIPLE])与常规疗法(STANDARD)用于经皮冠状动脉介入治疗后的患者的疗效和安全性。研究人员根据血栓弹力图(一种血小板功能检测)挑选了1078例经皮冠状动脉介入治疗

JAHA:我国≥75岁PCI患者负荷双联抗血小板治疗无临床获益且出血风险增加

在目前的临床实践中,所有接受PCI治疗的ACS患者均建议接受抗血小板药物的标准治疗,不论年龄大小。

急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议

抗血小板治疗可显著降低冠心病患者的血栓事件风险,国内外指南均将其作为急性冠状动脉综合征(acute coronary syndrome, ACS)治疗的Ⅰ类推荐。但临床实践中,抗血小板治疗的疗效和安全性呈现较大的个体差异,一些血栓和/或出血高风险的特殊患者,在接受常规抗血小板治疗时常发生血栓和出血事件,导致临床决策困难,亟须具体的指导性意见。因此,由中国医师协会心血管内科医师分会血栓防治专业委员会

Baidu
map
Baidu
map
Baidu
map